| 180 | 4 | 71 |
| 下载次数 | 被引频次 | 阅读次数 |
本次研究分析了Ⅰ型艾滋病病毒(HIV-1)感染者血浆中miRNA表达特点,探讨了血浆miRNA作为HIV-1感染及治疗监测生物学标志物的潜在可行性。选取2017年7月-2018年7月期间在昆明市第三人民医院就诊的HIV-1感染未经抗病毒治疗患者50例作为未治疗组,HIV-1感染经抗病毒治疗患者50例作为治疗组,选取同期本院健康体检者50例作为对照组,应用qPCR技术检测三组对象血浆miR-29a、miR-122,miR-155的相对表达量。结果显示,与健康对照组相比HIV-1感染未经抗病毒治疗组血浆miR-29a、miR-155、miR-122表达均升高,差异有统计学意义(P<0.05);未治疗组与治疗组相比较血浆miR-29a、miR-155和miR-122表达均升高,差异有统计学意义(P<0.05)。对未治疗组的研究显示,血浆miR-29a、miR-155表达水平与HIV-1RNA病毒载量呈正相关(P<0.05),miR-122与HIV-1RNA病毒载量无显著相关(P>0.05),miR-29a、miR-155表达水平与CD4~+T细胞计数呈负相关(P<0.05)。本研究提示HIV-1感染后血浆miRNA有变化,血浆miR-29a、miR-122,miR-155与HIV-1感染相关,可能是HIV-1感染的潜在生物学标志物。而抗病毒治疗可以诱导miR-29a、miR-155和miR-122表达降低,这些miRNA可能具有成为监测HIV-1感染抗病毒治疗效果观察指标的潜在价值。未治疗组血浆miR-29a、miR-155与HIV-1RNA呈正相关,表明其与HIV-1病毒复制相关。
Abstract：To investigate the feasibility of using microRNA (miR) expression in plasma as a biomarker for monitoring human immunodeficiency virus(HIV-1)infection and treatment.Relative expression of miR-29a,miR-122 and miR-155 in the plasma of 50 healthy controls,50 patients infected by HIV-1 who did not have antiviral treatment,and 50 patients infected with HIV-1 treated with antiviral agents was measured using realtime reverse transcription-quantitative polymerase chain reaction.Compared with the healthy control group,expression of miR-29a,miR-155 and miR-122 in plasma was increased in the untreated group(P<0.05).Compared with the treatment group,expression of miR-29a,miR-155 and miR-122 in plasma was higher in the untreated group(P<0.05).Expression of miR-29a and miR-155 in plasma in the untreated group was positively correlated with the viral load of HIV-1 RNA(P<0.05),but there was no significant correlation between miR-122 expression with the viral load of HIV-1 RNA(P>0.05).In the untreated group,expression of miR-29a and miR-155 was negatively correlated with CD4~+T-cell count(P<0.05).Changes in expression of miR-29a,miR-122 and miR-155 in plasma after HIV-1 infection were associated with HIV-1 infection.Antiviral therapy can induce reduced expression of miR-29a miR-155 and miR-122,and these three miRs may have value as observational indicators for monitoring the efficacy of antiviral therapy in HIV-1 infection.Expression of miR-29a and miR-155 was positively correlated with HIV-1 RNA load in the untreated group,indicating that it was correlated with HIV-1 replication.
[1] Günthard H F,Aberg J A,Eron J J,Hoy J F,Telenti A,Benson C A,Burger D M,Cahn P,Gallant J E,Glesby M J, Reiss P, Saag M S, Thomas D L,Jacobsen D M,Volberding P A,IAS-USA Panel.Antiretroviral treatment of adult HIV infection:2014recommendations of the international antiviral societyUSA panel[J]. JAMA,2014,312(4):410-425.
[2] Yeung M L, Bennasser Y, LE S Y, Jeang K T.siRNA,miRNA and HIV:promises and challenges[J].Cell Res,2005,(15):935-946.
[3] Biswas S, Haleyurgirisetty M, Lee S, Hewlett I,Devadas, K. Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection[J]. EBioMedicine,2019,43:307-316.
[4] Reynoso R, Laufer N, Hackl M, Skalicky S,Monteforte R,Turk G,Carobene M,Quarleri J,Cahn P,Werner R,Stoiber H,Grillari-Voglauer R,Grillari J. MicroRNAs differentially present in the plasma of HIV elite controllers reduce HIV infection in vitro[J].Sci Rep,2014,4:5915.
[5] Asahchop E L,Branton W G,Krishnan A,Chen P A,Yang D,Kong L,Zochodne D W,Brew B J,Gill M J,Power C. HIV-associated sensory polyneuropathy and neuronal injury are associated with miRNA-455-3p induction[J/OL]. JCI Insight,2018,3(23):e122450.
[6] Ahluwalia J K,Khan S Z,Soni K,Rawat P,Gupta A,Hariharan M,Scaria V,Lalwani M,Pillai B,Mitra D,Brahmachari S K. Human cellular microRNA hsa-miR-29a interferes with viral nef protein expression and HIV-1 replication[J]. Retrovirology,2008,5:117.
[7] Nathans R,Chu C Y,Serquina A K,Lu C C,Cao H,Rana T M. Cellular microRNA and P bodies modulate host-HIV-1 interactions[J]. Mol Cell,2009,34:696-709.
[8] Frattari G,Aagaard L,Denton P W. The role of miR-29a in HIV-1 replication and latency[J]. J Virus Erad,2017,3(4):185-191.
[9]王宇歌. HIV-1感染者血浆miRNA分布变化研究[D].北京：北京协和医学院，2012.
[10]Rosca A,Anton G,Botezatu A,Temereanca A,Ene L,Achim C,Ruta S. miR-29a associates with viroimmunological markers of HIV infection in treatment experienced patients[J]. J Med Virol,2016,88(12):2132-2137.
[11]Swaminathan G,Rossi F,Sierra L J,Gupta A,NavasMartín S,Martín-García J. A role for microRNA-155modulation in the anti-HIV-1 effects of Toll-like receptor 3 stimulation in macrophages[J/OL]. PLoS Pathog,2012,8(9):e1002937.
[12]Seddiki N,Swaminathan S,Phetsouphanh C,Kelleher A D. miR-155 is differentially expressed in Treg subsets,which may explain expression level differences of miR-155 in HIV-1 infected patients[J]. Blood,2012,119(26):6396-6397.
[13]Triboulet R,Mari B,Lin Y L,Chable-Bessia C,Bennasser Y,Lebrigand K,Cardinaud B,Maurin T,Barbry P,Baillat V,Reynes J,Corbeau P,Jeang K T,Benkirane M. Suppression of microRNA-silencing pathway by HIV-1 during virus replication[J]. Science,2007,315(5818):1579-1582.
[14]中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南（2015版）[J].中华临床感染病杂志，2015,8(5):385-401.
[15]中国疾病预防控制中心.全国艾滋病检测技术规范[M].2015.
[16]Chen X,Ba Y,Ma L,Cai X,Yin Y,Wang K,Guo J,Zhang Y,Chen J,Guo X,Li Q,Li X,Wang W,Zhang Y,Wang J,Jiang X,Xiang Y,Xu C,Zheng P,Zhang J,Li R,Zhang H,Shang X,Gong T,Ning G,Wang J,Zen K,Zhang J,Zhang C Y. Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases[J]. Cell Res,2008,18(10):997-1006.
[17]Witwer K W,Sarbanes S L,Liu J,Clements J E. A plasma microRNA signature of acute lentiviral infection:biomarkers of central nervous system disease[J]. AIDS(London,England),2011,25(17):2057-2067.
[18]杨鹏雅，何秀华，刘江福，林志鹏.无症状期HIV感染者外周血miR-155表达与T细胞亚群含量及病毒载量的关系[J/OL].病毒学报，2019,35(3):408-413. DOI:10.13242/j.cnki.bingduxuebao.003544.
[19]Biswas S, Haleyurgirisetty M, Lee S, Hewlett I,Devadas K. Development and validation of plasma miRNA biomarker signature panel for the detection of early HIV-1 infection[J]. EBio Medicine,2019,43:307-316.
[20]Patel P, Ansari M Y, Bapat S, Thakar M,Gangakhedkar R,Jameel S. The microRNA miR-29a is associated with human immunodeficiency virus latency[J]. Retrovirology,2014,11:108.
[21]Quinn S R,O'Neill L A. A trio of microRNAs that control Toll-like receptor signalling[J]. Int Immunol,2011,23(7):421-425.
[22]O'Neill L A,Sheedy F J,McCoy C E. MicroRNAs:the fine-tuners of Toll-like receptor signalling[J]. Nat Rev Immunol,2011,11(3):163-175.
[23]Ruelas D S, Chan J K, Oh E, Heidersbach A J,Hebbeler A M,Chavez L,Verdin E,Rape M,Greene W C. MicroRNA-155 reinforces hiv latency[J]. J Biol Chem,2015,290(22):13736-13748.
[24]Jopling C L,Yi M,Lancaster A M,Lemon S M,Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA[J]. Science,2005,309(5740):1577-1581.
[25]Jangra R K,Yi M,Lemon S M. Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122[J]. J Virol,2010,84(13):6615-6625.
[26]Fehr C, Conrad K D, Niepmann M. Differential stimulation of hepatitis C virus RNA translation by microRNA-122 in different cell cycle phases[J]. Cell Cycle,2012,11(2):277-285.
[27]Goergen D,Niepmann M. Stimulation of Hepatitis C Virus RNA translation by microRNA-122 occurs under different conditions in vivo and in vitro[J]. Virus Res,2012,167(2):343-352.
[28]ManfèV,Biskup E,Rosbjerg A,Kamstrup M,Skov A G, Lerche C M, Lauenborg B T, Odum N,Gniadecki R. miR-122 regulates p53/Aktsignalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma[J/OL]. PLoS One,2012,7(1):e29541.
[29]López-Huertas M R,Morín M,Madrid-Elena N,Gutiérrez C,Jiménez-Tormo L,Santoyo J,SanzRodríguez F, Moreno Pelayo Má，Bermejo L G,Moreno S. Selective miRNA modulation fails to activate HIV replication in in vitro latency models[J]. Mol Ther Nucleic Acids,2019,17:323-336.
[30]Modai S,Farberov L,Herzig E,Isakov O,Hizi A,Shomron N. HIV-1 infection increases microRNAs that inhibit Dicer1,HRB and HIV-EP2,thereby reducing viral replication[J/OL]. PLoS One,2019,14(1):e0211111.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.004066
中图分类号:R512.91
引用信息:
[1]闫新丽,李晓非,吕松琴,等.血浆microRNA与HIV感染及治疗关系的研究[J].病毒学报,2022,38(01):84-89.DOI:10.13242/j.cnki.bingduxuebao.004066.
基金信息:
昆明市科技局科技保障民生发展计划（项目号：昆科计字2019-1-S-25318000001232号），题目：血浆miRNA作为HIV-1感染生物标志物在感染和治疗中的研究~~
2020-09-11
2020
2020-11-12
2021-11-22
2021
2
2021-11-23
2021-11-23
2021-11-23